241 related articles for article (PubMed ID: 25683150)
1. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.
Bernichtein S; Pigat N; Camparo P; Latil A; Viltard M; Friedlander G; Goffin V
Prostate; 2015 May; 75(7):706-22. PubMed ID: 25683150
[TBL] [Abstract][Full Text] [Related]
2. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
Latil A; Libon C; Templier M; Junquero D; Lantoine-Adam F; Nguyen T
BJU Int; 2012 Sep; 110(6 Pt B):E301-7. PubMed ID: 22520557
[TBL] [Abstract][Full Text] [Related]
3. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
4. Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.
Sirab N; Robert G; Fasolo V; Descazeaud A; Vacherot F; de la Taille A; Terry S
Int J Mol Sci; 2013 Jul; 14(7):14301-20. PubMed ID: 23846725
[TBL] [Abstract][Full Text] [Related]
5. Hexanic Extract of Serenoa repens (Permixon
Blair HA
Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia.
Vacherot F; Azzouz M; Gil-Diez-De-Medina S; Colombel M; De La Taille A; Lefrère Belda MA; Abbou CC; Raynaud JP; Chopin DK
Prostate; 2000 Nov; 45(3):259-66. PubMed ID: 11074529
[TBL] [Abstract][Full Text] [Related]
9. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia.
Vela-Navarrete R; Escribano-Burgos M; Farré AL; García-Cardoso J; Manzarbeitia F; Carrasco C
J Urol; 2005 Feb; 173(2):507-10. PubMed ID: 15643230
[TBL] [Abstract][Full Text] [Related]
10. Effect of permixon on human prostate cell growth: lack of apoptotic action.
Hill B; Kyprianou N
Prostate; 2004 Sep; 61(1):73-80. PubMed ID: 15287095
[TBL] [Abstract][Full Text] [Related]
11. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL; Brogden RN
Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
[TBL] [Abstract][Full Text] [Related]
14. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.
Vela Navarrete R; Garcia Cardoso JV; Barat A; Manzarbeitia F; López Farré A
Eur Urol; 2003 Nov; 44(5):549-55. PubMed ID: 14572753
[TBL] [Abstract][Full Text] [Related]
15. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat.
Paubert-Braquet M; Richardson FO; Servent-Saez N; Gordon WC; Monge MC; Bazan NG; Authie D; Braquet P
Pharmacol Res; 1996; 34(3-4):171-9. PubMed ID: 9051712
[TBL] [Abstract][Full Text] [Related]
16. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
Amdii RE; Al' Shukri AS
Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
[TBL] [Abstract][Full Text] [Related]
17. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.
Paubert-Braquet M; Cousse H; Raynaud JP; Mencia-Huerta JM; Braquet P
Eur Urol; 1998; 33(3):340-7. PubMed ID: 9555564
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
[TBL] [Abstract][Full Text] [Related]
19. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
Bayne CW; Donnelly F; Ross M; Habib FK
Prostate; 1999 Sep; 40(4):232-41. PubMed ID: 10420151
[TBL] [Abstract][Full Text] [Related]
20. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
Buck AC
J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]